Page 1057 - Hall et al (2015) Principles of Critical Care-McGraw-Hill

4 References

88. Aksoy S, Dizdar O, Hayran M, Harputluoglu H. Infectious 104. Cornelissen JJ, de Graeff A, Verdonck LF, et al. Imipenem versus
complications of rituximab in patients with lymphoma during gentamicin combined with either cefuroxime or cephalothin
maintenance therapy: a systematic review and meta-analysis. as initial therapy for febrile neutropenic patients. Antimicrob
Leuk Lymphoma. March 2009;50(3):357-365. Agents Chemother. 1992;36(4):801-807.
89. Sonis ST, Elting LS, Keefe D, et al. Perspectives on cancer 105. Bow EJ. Fluoroquinolones, antimicrobial resistance and neu-
therapy-induced mucosal injury: pathogenesis, measurement, tropenic cancer patients. Curr Opin Infect Dis. December
epidemiology, and consequences for patients. Cancer. 2004; 2011;24(6):545-553.
100(9 suppl):1995-2025. 106. Peacock JE, Herrington DA, Wade JC, et al. Ciprofloxacin plus
90. Lockhart PB, Sonis ST. Relationship of oral complications piperacillin compared with tobramycin plus piperacillin as
to peripheral blood leukocyte and platelet counts in patients empirical therapy in febrile neutropenic patients: a randomized,
receiving cancer chemotherapy. Oral Surg Oral Med Oral Pathol. double-blind trial. Ann Intern Med. 2002;137(2):77-87.
1979;48(1):21-28. 107. Group EIATCP. Three antibiotic regimens in the treatment
91. Slavin RE, Dias MA, Saral R. Cytosine arabinoside induced of infection in febrile granulocytopenic patients with cancer.
gastrointestinal toxic alterations in sequential chemotherapeu- J Infect Dis. 1978;137(1):14-29.
tic protocols: a clinical-pathologic study of 33 patients. Cancer. 108. Group EIATCP. Combination of amikacin and carbenicillin
1978;42(4):1747-1759. with or without cefazolin as empirical treatment of febrile neu-
92. Sonis ST. Mucositis as a biological process: a new hypothesis for tropenic patients. J Clin Oncol. 1983;1(10):597-603.
the development of chemotherapy-induced stomatotoxicity 1. 109. Klastersky J, Glauser MP, Schimpff SC, Zinner SH, Gaya H,
Oral Oncol. 1998;34(1):39-43. Group EIATCP. Prospective randomized comparison of three
93. Bow EJ, Loewen R, Cheang MS, Shore TB, Rubinger M, Schacter B. antibiotic regimens for empirical theapy of suspected bactere-
Cytotoxic therapy-induced D-xylose malabsorption and inva- mic infection in febrile granulocytopenic patients. Antimicrobial
sive infection during remission-induction therapy for acute Agents Chemother. 1986;29(2):263-270.
myeloid leukemia in adults. J Clin Oncol. 1997;15(6):2254-2261.
110. Vancomycin added to empirical combination antibiotic therapy
94. Wardley AM, Jayson GC, Swindell R, et al. Prospective evalu- for fever in granulocytopenic patients. European Organization
ation of oral mucositis in patients receiving myeloablative for Research and Treatment of Cancer (EORTC) International
conditioning regimens and haemopoietic progenitor rescue. Br Antimicrobial Therapy Cooperative Group and the National
J Haematol. 2000;110(2):292-299. Cancer Institute of Canada-Clinical Trials Group. J Infect Dis.
95. Meropol NJ, Somer RA, Gutheil J, et al. Randomized phase I 1991;163:951-958.
trial of recombinant human keratinocyte growth factor plus 111. Efficacy and toxicity of single daily doses of amikacin and ceftri-
chemotherapy: potential role as mucosal protectant. J Clin axone versus multiple daily doses of amikacin and ceftazidime
Oncol. 2003;21(8):1452-1458. for infection in patients with cancer and granulocytopenia. The
96. Bow EJ, Loewen R, Cheang MS, Schacter B. Invasive fungal dis- International Antimicrobial Therapy Cooperative Group of the
ease in adults undergoing remission-induction therapy for acute European Organization for Research and Treatment of Cancer.
myeloid leukemia: the pathogenetic role of the antileukemic Ann Intern Med. 1993;119(7):584-593.
regimen. Clin Infect Dis. 1995;21(2):361-369. 112. Cometta A, Zinner S, De Bock R, et al. Piperacillin-tazobactam
97. Bochud PY, Eggiman P, Calandra T, Van Melle G, Saghafi L, plus amikacin versus ceftazidime plus amikacin as empiric
Francioli P. Bacteremia due to viridans streptococcus in therapy for fever in granulocytopenic patients with cancer. The
neutropenic patients with cancer: clinical spectrum and risk International Antimicrobial Therapy Cooperative Group of the
factors. Clin Infect Dis. 1994;18:25-31. European Organization for Research and Treatment of Cancer.
98. Cordonnier C, Buzyn A, Leverger G, et al. Epidemiology and Antimicrob Agents Chemother. 1995;39(2):445-452.
risk factors for gram-positive coccal infections in neutrope- 113. Cometta A, Calandra T, Gaya H, et al. Monotherapy with
nia: toward a more targeted antibiotic strategy. Clin Infect Dis. meropenem versus combination therapy with ceftazidime plus
2003;36(2):149-158. amikacin as empirical therapy for fever in granulocytope-
99. Sonis ST, Oster G, Fuchs H, et al. Oral mucositis and the clinical nic patients with cancer. Antimicrobial Agents Chemother.
and economic outcomes of hematopoietic stem-cell transplan- 1996;40(5):1108-1115.
tation. J Clin Oncol. 2001;19(8):2201-2205. 114. Pizzo PA, Hathorn JW, Hiemenz J, et al. A randomized trial
100. Elting LS, Shih YCT. The economic burden of supportive care of comparing ceftazidime alone with combination antibiotic ther-
cancer patients. Support Care Cancer. 2004;12(4):219-226. apy in cancer patients with fever and neutropenia. New Engl J
101. Cherif H, Kronvall G, Bjorkholm M, Kalin M. Bacteraemia in Med. 1986;315(9):552-558.
hospitalised patients with malignant blood disorders: a retro- 115. De Pauw BE, Deresinski SC, Feld R, Lane-Allman EF, Donnelly JP.
spective study of causative agents and their resistance profiles Ceftazidime compared with piperacillin and tobramycin for the
during a 14-year period without antibacterial prophylaxis. empiric treatment of fever in neutropenic patients with cancer.
Hematol J. 2003;4(6):420-426. Ann Intern Med. 1994;120(10):834-844.
102. Morris PG, Hassan T, McNamara M, et al. Emergence of MRSA 116. Del Favero A, Menichetti F, Martino P, et al. A multicenter,
in positive blood cultures from patients with febrile neutro- double-blind, placebo-controlled trial comparing piperacillin-
penia—a cause for concern. Support Care Cancer. September tazobactam with and without amikacin as empiric therapy for
2008;16(9):1085-1088. febrile neutropenia. Clin Infect Dis. 2001;33(8):1295-1301.
103. From the immunocompromised Host Society. The design, analysis 117. Freifeld AG, Walsh T, Marshall D, et al. Monotherapy for fever
and reporting of clinical trials on the empirical antibiotic manage- and neutropenia in cancer patients: a randomized comparison of
ment of the neutropenic patient. J Infect Dis. 1990;161:397-401. ceftazidime versus imipenem. J Clin Oncol. 1995;13(1):165-176.

Section05-O-ref.indd 4 1/20/2015 4:51:19 PM